Specific antibodies against S100A4 or fragment thereof, process for their preparation, pharmaceutical compositions containing them, a hybridoma cell line of the conjugates compositions, methods for preventing and / or treating cancer, metastasis, angiogenesis and inflammatory diseases, methods and kits for cancer diagnosis or disease associated WITH INFLAMMATION, METHOD FOR DETECTION S100A4, METHOD FOR CREATING INDIVIDUAL THERAPY

摘要

1. A specific anti-S100A4 antibody characterized by antiangiogenic activity, or a fragment thereof substantially retaining the antiangiogenic activity of said antibody, the antibody being produced by a hybridoma selected from the group consisting of ECACC 10022401, ECACC 11051801, ECACC 11051802, ECACC 11051803 and ECACC 11051803 and ECACC. The antibody or fragment thereof according to claim 1, which is produced by ECACC hybridoma 10022401.3. The antibody or fragment thereof according to claim 2, which contains at least a VL region and at least a VH region, wherein the VL region comprises the sequence of SEQ ID NO: 1, and the VH region includes the sequence of SEQ ID NO: 2.4. An antibody or fragment thereof according to any one of claims 1 to 3, which is characterized by the blocking of human endothelial cells to migration. A hybridoma cell line selected from the group comprising cell lines deposited under registration numbers ECACC 10022401, ECACC 11051801, ECACC 11051802, ECACC 11051803 and ECACC 11051804.6. A pharmaceutical composition comprising a pharmaceutically effective amount of at least one antibody or fragment thereof according to any one of claims 1 to 4 and at least one pharmaceutically acceptable carrier. The use of a specific anti-S100A4 antibody characterized by antiangiogenic activity, or a fragment thereof substantially retaining the antiangiogenic activity of said antibody, the antibody being selected from the group comprising an antibody recognizing the S1 OOA4 epitope containing the sequence ELPSFLGKRT (SEQ ID NO: 3), an antibody, recognizing an S100A4 epitope containing the sequence EGFPDKQPRKK (SEQ ID NO: 24) and an antibody produced by ECACC 11051804 hybridoma as a means of preventing and / or treating a disease, choose�